Dan Janney is the Managing Partner of Alta Partners. Dan joined Alta at its founding and has over 20 years of successful early stage investing experience in life sciences. His focus on working with exceptional entrepreneurs to create companies around novel insights in biology and new approaches to drug discovery has led to the funding and development of over 35 companies. Prior to Alta, Dan was a senior investment banker at Montgomery Securities where he advised life science companies on over $8 billion of equity and merger transactions.
Dan is currently on the board of directors of several public and private companies, including Alba Therapeutics, Esperion Therapeutics (NASDAQ:ESPR), Evolve Biosystems, Prolacta Bioscience, Sutro Biopharma, and Viveve (OTC:VIVMF). In addition, he led Alta’s investments in Astex Pharmaceuticals (acquired by Supergen), Cellective (acquired by Medimmune), ChemGenex (ASX:CXS acquired by Cephalon), CoTherix (NASDAQ: CTRX acquired by Actellion), Definity Health (acquired by United Health), Dynavax (NASDAQ:DVAX), Endonetics (acquired by Medtronic), Ilex Oncology (NASDAQ:ILXO acquired by Millennium Pharmaceuticals), InterMune (NASDAQ:ITMN acquired by Roche), LJL Biosystems (NASDAQ:LJLB acquired by Molecular Devices), Mako Surgical (NASDAQ:MAKO acquired by Stryker), Neothetics (NASDAQ:NEOT), and Triangle Pharmaceuticals (NASDAQ:VIRS acquired by Gilead).
In 2006 and 2007, Dan was listed in Forbes’ Midas 100 List of Top Tech Investors. He is a member of The President's Council of the J. David Gladstone Institutes and serves on the Board of Regents of Georgetown University. He holds a Bachelor of Arts in History from Georgetown University and a Master of Business Administration from the Anderson School at the University of California, Los Angeles.